Below is a detailed analysis of the quarterly data for 3B Blackbio DX Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 22.50 Cr.. The value appears to be declining and may need further review. It has decreased from 25.39 Cr. (Dec 2024) to 22.50 Cr., marking a decrease of 2.89 Cr..
For Expenses, as of Mar 2025, the value is 14.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.32 Cr. (Dec 2024) to 14.58 Cr., marking an increase of 4.26 Cr..
For Operating Profit, as of Mar 2025, the value is 7.92 Cr.. The value appears to be declining and may need further review. It has decreased from 15.07 Cr. (Dec 2024) to 7.92 Cr., marking a decrease of 7.15 Cr..
For OPM %, as of Mar 2025, the value is 35.20%. The value appears to be declining and may need further review. It has decreased from 59.35% (Dec 2024) to 35.20%, marking a decrease of 24.15%.
For Other Income, as of Mar 2025, the value is 4.94 Cr.. The value appears strong and on an upward trend. It has increased from 3.01 Cr. (Dec 2024) to 4.94 Cr., marking an increase of 1.93 Cr..
For Interest, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
For Depreciation, as of Mar 2025, the value is 0.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Dec 2024) to 0.28 Cr., marking an increase of 0.01 Cr..
For Profit before tax, as of Mar 2025, the value is 12.54 Cr.. The value appears to be declining and may need further review. It has decreased from 17.79 Cr. (Dec 2024) to 12.54 Cr., marking a decrease of 5.25 Cr..
For Tax %, as of Mar 2025, the value is 35.89%. The value appears to be increasing, which may not be favorable. It has increased from 24.17% (Dec 2024) to 35.89%, marking an increase of 11.72%.
For Net Profit, as of Mar 2025, the value is 8.04 Cr.. The value appears to be declining and may need further review. It has decreased from 13.49 Cr. (Dec 2024) to 8.04 Cr., marking a decrease of 5.45 Cr..
For EPS in Rs, as of Mar 2025, the value is 9.79. The value appears to be declining and may need further review. It has decreased from 15.61 (Dec 2024) to 9.79, marking a decrease of 5.82.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:22 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
22
19
17
16
23
23
29
227
81
62
74
96
Expenses
21
18
16
14
18
16
20
77
44
33
41
46
Operating Profit
1
1
2
3
5
7
9
150
37
29
33
50
OPM %
6%
7%
9%
16%
23%
31%
32%
66%
46%
47%
44%
52%
Other Income
0
0
0
0
0
1
2
3
7
7
13
15
Interest
1
1
1
1
1
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
1
1
1
1
1
1
1
Profit before tax
0
0
0
1
5
7
10
152
43
35
44
64
Tax %
14%
23%
23%
19%
24%
25%
23%
25%
26%
27%
28%
25%
Net Profit
0
0
0
1
3
5
8
114
32
26
32
48
EPS in Rs
0.59
0.36
0.51
1.76
5.35
8.18
10.24
151.66
42.89
34.55
37.40
55.52
Dividend Payout %
-0%
-0%
-0%
17%
9%
6%
7%
6%
24%
8%
8%
-0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
200.00%
66.67%
60.00%
1325.00%
-71.93%
-18.75%
23.08%
50.00%
Change in YoY Net Profit Growth (%)
0.00%
-133.33%
-6.67%
1265.00%
-1396.93%
53.18%
41.83%
26.92%
3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
18%
5 Years:
27%
3 Years:
6%
TTM:
30%
Compounded Profit Growth
10 Years:
70%
5 Years:
44%
3 Years:
14%
TTM:
48%
Stock Price CAGR
10 Years:
67%
5 Years:
53%
3 Years:
64%
1 Year:
26%
Return on Equity
10 Years:
29%
5 Years:
30%
3 Years:
17%
Last Year:
19%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
0
0
1
1
2
4
7
98
37
20
27
43
Cash from Investing Activity +
-0
-0
-0
-0
-1
-1
-1
-70
-28
15
-20
-34
Cash from Financing Activity +
0
-0
-1
-0
0
-1
1
-2
-15
-5
-4
-3
Net Cash Flow
0
-0
0
0
1
2
7
26
-6
30
3
6
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
220
213
262
283
321
259
290
252
56
136
200
179
Inventory Days
149
120
145
143
175
164
141
Days Payable
220
189
218
203
186
69
66
Cash Conversion Cycle
149
144
188
223
310
259
290
252
56
136
296
253
Working Capital Days
214
218
274
312
377
308
351
302
67
169
248
216
ROCE %
8%
7%
7%
7%
13%
24%
28%
31%
162%
27%
19%
21%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Promoters
38.35%
38.35%
38.43%
38.43%
38.43%
38.43%
38.43%
38.43%
38.43%
38.43%
38.43%
41.29%
FIIs
1.47%
0.54%
1.23%
1.64%
1.64%
1.64%
2.11%
2.54%
3.06%
3.16%
3.38%
2.97%
DIIs
0.09%
0.08%
0.08%
0.08%
0.08%
0.00%
0.00%
0.00%
0.00%
0.82%
1.18%
1.89%
Public
60.09%
61.03%
60.26%
59.85%
59.85%
59.94%
59.47%
59.02%
58.50%
57.60%
56.99%
53.85%
No. of Shareholders
10,541
16,251
16,756
16,468
16,316
15,415
13,798
13,136
12,416
10,513
10,088
9,753
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
55.66
37.40
34.55
43.40
151.66
Diluted EPS (Rs.)
55.66
37.40
34.55
43.40
151.66
Cash EPS (Rs.)
56.93
38.70
35.77
43.88
152.82
Book Value[Excl.RevalReserv]/Share (Rs.)
313.27
263.15
261.50
229.69
197.92
Book Value[Incl.RevalReserv]/Share (Rs.)
313.27
263.15
261.50
229.69
197.92
Revenue From Operations / Share (Rs.)
112.59
86.51
82.54
107.65
302.66
PBDIT / Share (Rs.)
76.08
53.12
48.55
58.73
204.07
PBIT / Share (Rs.)
74.82
51.88
47.40
57.84
203.25
PBT / Share (Rs.)
74.69
51.74
47.13
57.69
202.94
Net Profit / Share (Rs.)
55.66
37.46
34.62
42.98
152.00
NP After MI And SOA / Share (Rs.)
55.61
37.46
34.62
42.98
152.00
PBDIT Margin (%)
67.57
61.40
58.81
54.56
67.42
PBIT Margin (%)
66.45
59.97
57.42
53.72
67.15
PBT Margin (%)
66.34
59.80
57.10
53.59
67.05
Net Profit Margin (%)
49.43
43.30
41.94
39.92
50.21
NP After MI And SOA Margin (%)
49.39
43.30
41.94
39.92
50.21
Return on Networth / Equity (%)
17.75
14.39
15.14
21.04
86.23
Return on Capital Employeed (%)
23.13
19.28
17.76
24.73
101.13
Return On Assets (%)
16.11
12.93
12.11
16.76
58.83
Long Term Debt / Equity (X)
0.00
0.00
0.01
0.01
0.01
Total Debt / Equity (X)
0.00
0.00
0.01
0.01
0.01
Asset Turnover Ratio (%)
0.35
0.32
0.30
0.13
0.38
Current Ratio (X)
7.11
7.04
8.05
4.82
2.76
Quick Ratio (X)
6.64
6.56
7.49
4.38
2.64
Inventory Turnover Ratio (X)
3.03
2.41
2.33
2.66
2.68
Interest Coverage Ratio (X)
600.85
365.87
183.32
413.58
669.53
Interest Coverage Ratio (Post Tax) (X)
440.55
259.05
131.73
303.65
499.68
Enterprise Value (Cr.)
1319.35
600.55
278.94
248.35
196.43
EV / Net Operating Revenue (X)
13.68
8.10
4.51
3.08
0.86
EV / EBITDA (X)
20.24
13.19
7.67
5.64
1.28
MarketCap / Net Operating Revenue (X)
14.36
8.90
5.04
3.17
0.94
Price / BV (X)
5.16
2.96
1.82
1.67
1.62
Price / Net Operating Revenue (X)
14.36
8.90
5.04
3.17
0.94
EarningsYield
0.03
0.04
0.08
0.12
0.53
After reviewing the key financial ratios for 3B Blackbio DX Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
For Diluted EPS (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.66, marking an increase of 18.26.
For Cash EPS (Rs.), as of Mar 25, the value is 56.93. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 56.93, marking an increase of 18.23.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 112.59. It has increased from 86.51 (Mar 24) to 112.59, marking an increase of 26.08.
For PBDIT / Share (Rs.), as of Mar 25, the value is 76.08. This value is within the healthy range. It has increased from 53.12 (Mar 24) to 76.08, marking an increase of 22.96.
For PBIT / Share (Rs.), as of Mar 25, the value is 74.82. This value is within the healthy range. It has increased from 51.88 (Mar 24) to 74.82, marking an increase of 22.94.
For PBT / Share (Rs.), as of Mar 25, the value is 74.69. This value is within the healthy range. It has increased from 51.74 (Mar 24) to 74.69, marking an increase of 22.95.
For Net Profit / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.61. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.61, marking an increase of 18.15.
For PBDIT Margin (%), as of Mar 25, the value is 67.57. This value is within the healthy range. It has increased from 61.40 (Mar 24) to 67.57, marking an increase of 6.17.
For PBIT Margin (%), as of Mar 25, the value is 66.45. This value exceeds the healthy maximum of 20. It has increased from 59.97 (Mar 24) to 66.45, marking an increase of 6.48.
For PBT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has increased from 59.80 (Mar 24) to 66.34, marking an increase of 6.54.
For Net Profit Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 10. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 49.39. This value exceeds the healthy maximum of 20. It has increased from 43.30 (Mar 24) to 49.39, marking an increase of 6.09.
For Return on Networth / Equity (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has increased from 14.39 (Mar 24) to 17.75, marking an increase of 3.36.
For Return on Capital Employeed (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has increased from 19.28 (Mar 24) to 23.13, marking an increase of 3.85.
For Return On Assets (%), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.93 (Mar 24) to 16.11, marking an increase of 3.18.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.35. It has increased from 0.32 (Mar 24) to 0.35, marking an increase of 0.03.
For Current Ratio (X), as of Mar 25, the value is 7.11. This value exceeds the healthy maximum of 3. It has increased from 7.04 (Mar 24) to 7.11, marking an increase of 0.07.
For Quick Ratio (X), as of Mar 25, the value is 6.64. This value exceeds the healthy maximum of 2. It has increased from 6.56 (Mar 24) to 6.64, marking an increase of 0.08.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.03. This value is below the healthy minimum of 4. It has increased from 2.41 (Mar 24) to 3.03, marking an increase of 0.62.
For Interest Coverage Ratio (X), as of Mar 25, the value is 600.85. This value is within the healthy range. It has increased from 365.87 (Mar 24) to 600.85, marking an increase of 234.98.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 440.55. This value is within the healthy range. It has increased from 259.05 (Mar 24) to 440.55, marking an increase of 181.50.
For Enterprise Value (Cr.), as of Mar 25, the value is 1,319.35. It has increased from 600.55 (Mar 24) to 1,319.35, marking an increase of 718.80.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 8.10 (Mar 24) to 13.68, marking an increase of 5.58.
For EV / EBITDA (X), as of Mar 25, the value is 20.24. This value exceeds the healthy maximum of 15. It has increased from 13.19 (Mar 24) to 20.24, marking an increase of 7.05.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.96 (Mar 24) to 5.16, marking an increase of 2.20.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of 3B Blackbio DX Ltd as of June 26, 2025 is: 1,241.33
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, 3B Blackbio DX Ltd is Overvalued by 12.27% compared to the current share price 1,415.00
Intrinsic Value of 3B Blackbio DX Ltd as of June 26, 2025 is: 1,015.32
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, 3B Blackbio DX Ltd is Overvalued by 28.25% compared to the current share price 1,415.00
Last 5 Year EPS CAGR: -18.21%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in 3B Blackbio DX Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 17.75% (Industry Average ROE: 19.94%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 25.5 (Industry average Stock P/E: 37.37)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
3B BlackBio Dx Ltd. is a Public Limited Listed company incorporated on 27/05/1972 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L24211MP1972PLC001131 and registration number is 001131. Currently Company is involved in the business activities of Manufacture of pesticides and other agrochemical products. Company's Total Operating Revenue is Rs. 90.53 Cr. and Equity Capital is Rs. 8.57 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in 3B Blackbio DX Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
